



## Update: Lomustine (CCNU) Discontinuation Announcement by Bristol Myers Squibb

On March 24<sup>th</sup>, 2022, members of the Brain Tumour Foundation of Canada Advocacy Committee met with representatives from Bristol Myers Squibb to discuss their announced decision to discontinue the supply and distribution of lomustine (CCNU), brand name CeeNU<sup>®</sup>, in Canada in June, 2023. We expressed our concern about the effects that this discontinuation would have on the brain tumour community.

After this meeting, we received communications from Bristol Myers Squibb indicating that the date for the discontinuation of lomustine in Canada has been extended to March 31<sup>st</sup>, 2025.

You may view the updated discontinuation report for 40MG on the [Drug Shortages Canada website](#).

You may view the updated discontinuation report for 10MG on the [Drug Shortages Canada website](#).

For more information, or to learn more about our ongoing advocacy efforts, please contact:

Sarah Rogers, Advocacy and Information Services Specialist  
srogers@braintumour.ca